🔗 Share this article

While America undertakes unprecedented changes to its immunization recommendations, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus shots during the pandemic and has zeroed in on alleged deaths after COVID-19 vaccination in her brief time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Schedule

Health officials had intended to announce sweeping revisions to the childhood vaccine schedule in December, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with a large portion of the world with insufficient data for public health gain. The planned update has been postponed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to present at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

Consolidating Power at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a greater focus upon rolling back long-standing vaccines at the FDA.

The new acting director has frequently advocated for discontinuing certain pediatric immunization guidelines in the US in order to be more like the Danish model, a nation with comprehensive healthcare and a population roughly the population of Wisconsin’s.

To date public appearances, she has continued to focus on immunizations – typically the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Expertise

The appointee has no obvious track record in drug development, regulation or administrative roles, which has been customary for past leaders of the biologics center. She has served at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, stated Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a major agency. She is not an expert in drug approvals.”

Past heads of the center would “grasp laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that prior appointees who headed the center have had.”

This division has an enormous range of responsibilities at the agency, Woodcock stated.

“The public just focuses on the new drug program, but the generic drug division clears numerous generic medications. There’s a biosimilars division, OTC medication office and more, and each of these must be looked after,” Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial administrative aspect to the position, which manages over 5,000 personnel. “It is a massive leadership role, if you do it right,” the former official concluded.

Agency Reaction and Contentious Policies

Regarding concerns about Høeg’s qualifications and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a press secretary stated that the “inquiries rely on incorrect presumptions”.

“Her experience matches the responsibilities of her role,” the official explained, citing the time Dr. Høeg spent advising the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg takes over the agency head's new fast-track approval initiative, a contentious one-day drug-approval program that apparently troubled her preceding directors. “By what process are these medications being chosen for this fast-track system? Who makes the calls?” Dr. Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent regulations of most medications, aside from immunizations.”

Public Track Record on Immunizations

Concerning vaccines, Høeg has a more documented, if troubling, track record, Howard have noted. She published a analysis using unverified crowd-sourced reports to determine the rate of myocarditis following Covid immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership featured revising regulations for recently developed shots and ending “non-essential” immunizations, she remarked following the vote on a audio program. At the FDA, Høeg has allegedly floated the idea of excluding adolescent males from obtaining COVID-19 vaccines.

“She is an thorough dogmatist who starts off with her beliefs and works backwards to retrofit the evidence in a extremely disingenuous, dishonest fashion,” Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg became part of fellow contrarians, {like|